Constellation Pharmaceuticals Provides Update on MANIFEST Clinical Trial of CPI-0610

Constellation Pharmaceuticals (Nasdaq:CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today provided an...

Constellation Pharmaceuticals Initiates Phase 2 Portion of ProSTAR Clinical Trial in Patients

Constellation Pharmaceuticals (Nasdaq:CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, announced an update...

Constellation Pharmaceuticals Enhances and Expands Phase 2 MANIFEST Study of CPI-0610

Constellation Pharmaceuticals (Nasdaq:CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced several...

5 Pharmaceutical IPOs in July

These companies have recently completed the steps to join the public market, allowing more opportunities for pharmaceutical investors.